NHS UDA delivery rates: the headline figures

NHS UDA delivery — the measure of contracted dental activity fulfilled under the NHS dental contract — is a single statistic doing a lot of political work at the moment. According to commentary by Peter Ingle published on GDPUK, drawing on delivery data made accessible through the Oralytics platform, national UDA delivery has risen from 81.8% in 2024/5 to 87.1% in 2025/6 — an improvement of 5.3 percentage points. The same piece reports 6.4 million UDAs delivered in April 2026, continuing a post-pandemic recovery from 6.1 million in April 2025, 5.8 million in April 2024 and 4.8 million in April 2023.

Those are Oralytics' figures, derived from contract delivery data. The NHSBSA's official statistics do not publish a delivery rate against contract, so the percentage cannot be read off the national tables, but the official count points the same way: 76.8 million UDAs were delivered in England in 2025/26, up 5.1% on 73.1 million the year before, though still 3.7% short of the 79.7 million delivered in 2019/20. The trend is not in serious dispute, and for a health minister it makes a tidy story: things were in a mess, and now they are measurably better.

The trouble is what the number actually measures — and, more importantly, what it does not.

A delivery percentage is not a quality metric

A UDA is a unit of contracted activity, weighted by treatment band. It is not a measure of disease control, treatment outcome or population oral health. Two practices delivering identical UDA numbers can carry very different case-mix, complexity and clinical results. So a rising delivery percentage tells you that more of the contracted work is being completed; it tells you nothing about whether patients are being seen early enough, often enough, or well enough. Reading "delivery is up" as "dentistry is improving" is a category error, and a clinical readership should not let it pass unchallenged.

For the practices that have avoided clawback, breach letters and the familiar year-end scramble for last-minute UDAs, the improvement is a genuine relief. But it is a defensive win, not a growth one. Hitting target keeps income already banked from being recovered. It does not raise the UDA tariff, the fee per unit or the margin — all of which remain under real-terms pressure from inflation and staff costs. Meeting your target avoids a penalty; it does not improve your economics.

The composition question — and a warning against treating it as settled

Ingle's central argument is that the mix of UDAs will shift. As available units are increasingly earned seeing unscheduled attenders and complex-care patients — many with irregular attendance histories, some with the consequences of prolonged neglect — a larger slice of the UDA cake goes to those groups, leaving less for the stable recall patients who have traditionally formed the predictable base of a mixed practice.

It is a coherent narrative, and much of the sector commentary treats it as an established trend. It is worth being clear that it is not. The source presents no data breaking UDA delivery down by patient type; it offers a plausible reading of where marginal capacity is likely to go, not a measured shift already observed. That distinction matters, because every downstream worry — the squeeze on recall patients, the funding risk, the operational strain — inherits whatever uncertainty sits in that first assumption. Treat it as a scenario to plan against, not a fact to react to.

With that caveat firmly in place, the scenario is plausible enough to be worth planning for.

What it would mean operationally

If the mix does shift as Ingle suggests, the operational consequences are real. Complex and neglected-patient caseloads generally need more chair time, more experienced clinical judgement and longer consent discussions than routine recalls — yet a complex case and a straightforward check-up may attract the same UDA credit within a band. That means the same compliance figure can coincide with worse throughput economics per session: more time spent, no more units earned.

Three practical responses are worth considering now rather than after the fact:

• Diary design. Unscheduled-care slots are better built into the working week deliberately than absorbed as ad hoc disruption. Left unmanaged, emergency demand cannibalises recall capacity and squeezes out exactly the known patients a practice most wants to retain.
• Skill mix. If your NHS list has leaned on associates delivering high-volume simple examinations, a shift towards complex and irregular attenders may require re-rostering towards more experienced clinicians.
• Governance and continuity. More first-time and irregular patients means less shared clinical history at the point of treatment decisions. The long-standing medicolegal caution about treating unfamiliar patients becomes harder to observe when new patients move quickly into complex care. Reviewing consent processes and record-keeping standards is a sensible pre-emptive step, not a reaction to an incident.

The funding cliff nobody controls: PCR

There is a quieter financial risk here. Ingle notes that Patient Charge Revenue — the patient-funded portion of NHS dental costs — is estimated at around a quarter of the gross cost of primary care dentistry, and that a drop in PCR helped kill off some earlier pilots because the Treasury took a dim view. Our reading is that if the incoming patient mix skews towards exemption categories or lower-charge bands, PCR could fall at practice level even while UDA volume holds. Owners would be wise to track their own PCR-to-UDA ratio rather than assume it is stable — it is a leading indicator of a funding pressure that has historically triggered central intervention.

Ingle also raises a point that will interest anyone watching local commissioning: reduced clawback is not unambiguously good for Integrated Care Boards. Recovered money has, in the absence of an effective ringfence, sometimes plugged non-dental holes or funded local access initiatives. Whether the new national unscheduled-care arrangements provide as effective a safety valve as the older local schemes — some of which were more generous — remains to be seen.

What this means for your marketing — mostly, leave the statistic alone

The temptation to turn a good national number into a reassurance message should be resisted. The UDA delivery percentage has no place in any patient-facing communication. Using it to imply that NHS access is improving — nationally or, worse, at your practice — is an unsubstantiated comparative claim of exactly the kind the CAP Code targets, and the analysis itself is explicit that national delivery does not equate to individual access or outcomes.

The honest communications opportunity is the opposite of a boast. If stable recall patients are at risk of being pushed down the list, getting ahead of their frustration with clear, local, factual messaging — what is changing, and how the practice is managing capacity to keep looking after existing patients — is a retention message, not a promotion. For mixed and private practices, a private recall or membership option can be framed as a genuine continuity benefit, but never in a way that implies NHS care is inferior or that a patient's health is at risk if they do not pay. Fear-based framing around access breaches both CAP rules and GDC guidance on not exploiting patient anxiety.

On that note, Ingle's rhetorical flourish — that patients at the back of the queue might suffer a painful infection or a delayed mouth-cancer diagnosis — is effective as commentary but is not supported by any evidence in the source linking UDA shortfalls to presentation stage or emergency rates. It reads as illustrative worst-case framing. It must not be repeated as a causal claim in advertising, patient letters or even internal recall-reminder wording.

A final clinical caveat for anyone tempted to standardise recall policy in response to capacity pressure: NICE guidance (CG19) is risk-based, not a blanket biennial interval. Intervals should vary by individual caries, periodontal and soft-tissue risk, age and history. Presenting a fixed two-year check-up as standard for everyone would misrepresent individualised care.

The bottom line

The minister may be well advised to enjoy the good UDA news while it lasts, as Ingle drily suggests. For practice owners, the non-obvious insight is this: an improving delivery percentage and a worsening per-session economics can happen at the same time, and the number that would warn you — your own PCR-to-UDA ratio and your average appointment length by case type — is one you have to measure for yourself. The headline is a sector-reputation story. Your commercial reality is a spreadsheet only you can see.